Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

GH PEER ANALYSIS

Guardant Health Inc — metric-by-metric comparison with peers and the industry median

GHGuardant Health Inc

🇺🇸 USA · NASDAQ · Healthcare · Diagnostics & Research

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Diagnostics & Research

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
GHIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
GH+207.3%ERF+13.7%SHL-14.9%
Year-to-Date (YTD)
GH+52.9%ERF+8.7%SHL-1.5%
1-Year
Split-adjusted
GH+207.3%LH+9.0%DGX+22.3%MTD+3.5%ILMN+89.2%MEDP+65.0%
Year-to-Date (YTD)
GH+52.9%LH+11.3%DGX+21.1%MTD-10.4%ILMN+43.2%MEDP-5.3%

Key Metric Comparison

P/E

Lower is better
GH—ERF26.40SHL20.03Median 28.95

ROE

Higher is better
GH—ERF10.7%SHL6.4%Median 6.4%

Net Margin

Higher is better
GH-40.1%ERF6.5%SHL5.2%Median 6.7%

Revenue Growth

Higher is better
GH39.6%ERF5.0%SHL11.4%Median 9.1%

P/E

Lower is better
GH—LH24.46DGX22.82MTD28.95ILMN33.91MEDP33.47Median 28.95

ROE

Higher is better
GH—LH11.1%DGX14.3%MTD—ILMN33.8%MEDP77.3%Median 6.4%

Net Margin

Higher is better
GH-40.1%LH6.7%DGX9.1%MTD21.4%ILMN19.4%MEDP17.2%Median 6.7%

Revenue Growth

Higher is better
GH39.6%LH7.3%DGX11.0%MTD6.8%ILMN1.2%MEDP24.2%Median 9.1%

All Metrics

Valuation
MetricGHERFSHLInd. Median
P/E—26.4020.03●28.95
P/B-113.22●3.541.263.39
EV/EBITDA—11.869.80●20.39
P/S18.981.721.04●4.21
Financial Health
MetricGHERFSHLInd. Median
Current Ratio4.68●1.091.011.87
Debt/Equity-941.4%●153.3%85.8%49.3%
NetDebt/EBITDA-1.54●3.203.781.92
Profitability
MetricGHERFSHLInd. Median
Net Margin-40.1%6.5%●5.2%6.7%
ROE—10.7%●6.4%6.4%
ROA-26.6%4.3%●3.3%3.3%
EBITDA Margin-36.2%19.9%●17.3%18.8%
Growth + Dividend
MetricGHERFSHLInd. Median
Rev. Growth39.6%●5.0%11.4%9.1%
NI Growth—16.9%●-1.1%12.4%
Div. Yield—1.0%5.2%●0.8%
Payout—23.2%96.9%23.2%
Valuation
MetricGHLHDGXMTDILMNMEDPInd. Median
P/E—24.4622.82●28.9533.9133.4728.95
P/B-113.222.643.17-604.95●10.8125.753.39
EV/EBITDA—14.2014.09●21.9621.5324.8020.39
P/S18.981.63●2.076.206.595.754.21
Financial Health
MetricGHLHDGXMTDILMNMEDPInd. Median
Current Ratio4.68●1.731.181.201.750.851.87
Debt/Equity-941.4%83.0%94.8%-5,321.1%●95.1%20.4%49.3%
NetDebt/EBITDA-1.54●3.033.101.730.99-0.881.92
Profitability
MetricGHLHDGXMTDILMNMEDPInd. Median
Net Margin-40.1%6.7%9.1%21.4%●19.4%17.2%6.7%
ROE—11.1%14.3%—33.8%77.3%●6.4%
ROA-26.6%5.1%6.3%25.4%●13.4%22.9%3.3%
EBITDA Margin-36.2%14.6%18.8%30.6%32.1%●22.4%18.8%
Growth + Dividend
MetricGHLHDGXMTDILMNMEDPInd. Median
Rev. Growth39.6%●7.3%11.0%6.8%1.2%24.2%9.1%
NI Growth—28.8%●14.2%3.0%—10.6%12.4%
Div. Yield—1.0%1.5%●———0.8%
Payout—25.5%34.9%———23.2%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on GH

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.